Manon Cox, PhD, MBA

Dr. Manon M.J. Cox is the founder and CEO of NextWaveBio and serves as a director of Vaxxas and GPN Vaccines, both clinical-stage vaccine development companies. She spent two decades at Protein Sciences Corporation in roles including Director of Business Development and Chief Operating Officer before becoming President and CEO, leading the development of Flublok^®, the only FDA-approved recombinant influenza vaccine, until the company’s acquisition by Sanofi in 2018.

Dr. Cox also serves on the Boards of the Netherlands America Foundation (NAF) and the International Society for Vaccines (ISV), where she will serve as President for the period 2026–2027. She contributes to various scientific advisory committees and has been widely recognised for her leadership in biotechnology and influenza innovation, receiving honors including a Doctorate in Humane Letters from St. Joseph University. She holds a Doctorate from Wageningen University, an MBA with distinction from Nyenrode and the University of Rochester, and a Doctorandus degree in Molecular Biology, Genetics, and Biochemistry from the University of Nijmegen.